Lv3
208 积分 2025-07-22 加入
生物制剂在我国溃疡性结肠炎治疗中的应用现状及优化建议
3天前
已完结
银屑病生物制剂长期维持治疗的专家指导意见
1个月前
已完结
Su1662 HEPATIC SAFETY OF INTERLEUKIN-23P19 INHIBITORS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A REAL-WORLD STUDY
1个月前
已完结
Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial
4个月前
已完结
Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial
4个月前
已完结
Comparative efectiveness of mirikizumab and risankizumab in patients with ulcerative colitis: A propensity‑matched cohort study
4个月前
已完结
Comparative effectiveness of mirikizumab and risankizumab in patients with ulcerative colitis: A propensity-matched cohort study
4个月前
已完结
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study
7个月前
已完结
IgG4-related disease: an update on pathophysiology and implications for clinical care
7个月前
已完结
皖公网安备34019202002308
